Difference between revisions of "Profiles"
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles=== | ===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles=== | ||
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | * [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | ||
| + | :* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.5 Dec-2014]] | ||
| + | :* [[Media:UPICT Oncologic FDG-PETCTProtocol 5-20-14.pdf|UPICT Protocol - Oncology FDG-PET CT 05-20-2014]] | ||
| − | |||
| − | |||
| − | |||
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ||
| − | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease | + | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]] |
| − | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist | + | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] |
| + | |||
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]] | * [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]] | ||
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]] | :* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]] | ||
| Line 32: | Line 32: | ||
:*[[Media:QIBA Small Nodule Profile References - Accuracy.xlsx|Spreadsheet: Small Nodule Profile References - Accuracy]] | :*[[Media:QIBA Small Nodule Profile References - Accuracy.xlsx|Spreadsheet: Small Nodule Profile References - Accuracy]] | ||
:*[[Media:QIBA Small Nodule Profile References - Precision.xlsx|Spreadsheet: Small Nodule Profile References - Precision]] | :*[[Media:QIBA Small Nodule Profile References - Precision.xlsx|Spreadsheet: Small Nodule Profile References - Precision]] | ||
| + | |||
==Statements of Endorsement== | ==Statements of Endorsement== | ||
Revision as of 18:11, 21 September 2017
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
The following Profiles are open for Public Comment:
- QIBA fMRI Profile 2017-06-19 Open until September 19, 2017
Please submit all public comments through the following online form: http://tinyurl.com/QIBA-Public-Comment-Form
(Note: each form accommodates 10 comments; you may submit additional forms as necessary)
Public Comment closed for the following Profiles (comment resolution is currently underway):
- QIBA PET Amyloid Profile 2017-06-15 (Closed on September 15, 2017)
- QIBA MRE Profile 2017-08-15 (Closed on September 15, 2017)
- DWI Profile 2017-04-27 (Closed on August 25, 2017)
- QIBA Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening Profile 2016-06-01 (Closed Sept 2016)
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)